Preoperative gemcitabine-based chemoradiation therapy for pancreatic ductal adenocarcinoma of the body and tail: Impact of splenic vessels involvement on operative outcome and pattern of recurrence

Surgery (United States)

Volumn 157, Issue 3, 2015, Pages 484-495

  Takahashi, Hidenori ^a   Akita, Hirofumi ^a   Gotoh, Kunihito ^a   Kobayashi, Shogo ^a   Marubashi, Shigeru ^a   Miyoshi, Norikatsu ^a   Sugimura, Keijiro ^a   Motoori, Masaaki ^a   Kishi, Kentaro ^a   Noura, Shingo ^a   Fujiwara, Yoshiyuki ^a   Ohue, Masayuki ^a   Ohigashi, Hiroaki ^a   Yano, Masahiko ^a   Sakon, Masato ^a   Ishikawa, Osamu ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE;

ABDOMINAL ABSCESS; ADRENAL GLAND; AGED; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHYLOUS ASCITES; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED GASTRIC EMPTYING; DIARRHEA; DUODENUM; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; INTERSTITIAL PNEUMONIA; LEUKOPENIA; LYMPH VASCULAR INVASION; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NOTE; OUTCOME ASSESSMENT; PANCREAS ADENOCARCINOMA; PANCREAS FISTULA; PANCREAS PSEUDOCYST; PANCREAS RESECTION; PERINEURAL INVASION; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION INJURY; RECURRENT DISEASE; REFRACTORY CHYLOUS ASCITES; REPEATED DRUG DOSE; SPLEEN ARTERY; SPLENIC VEIN; SURGICAL MORTALITY; THROMBOCYTOPENIA; TRANSVERSE COLON; TUMOR INVASION; TUMOR VOLUME; ADENOCARCINOMA; ADULT; ANALOGS AND DERIVATIVES; CARCINOMA, PANCREATIC DUCTAL; MIDDLE AGED; MORTALITY; PANCREATIC NEOPLASMS; PATHOLOGY; SURGERY; TUMOR RECURRENCE;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, PANCREATIC DUCTAL; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PANCREATIC NEOPLASMS; SPLENIC ARTERY; SPLENIC VEIN;

EID: 84923538280     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2014.09.022     Document Type: Article

References (35)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
2. M.F. Brennan, R.D. Moccia, and D. Klimstra Management of adenocarcinoma of the body and tail of the pancreas Ann Surg 223 1996 506 511 discussion 511-2
3. J.D. Christein, M.L. Kendrick, C.W. Iqbal, D.M. Nagorney, and M.B. Farnell Distal pancreatectomy for resectable adenocarcinoma of the body and tail of the pancreas J Gastrointest Surg 9 2005 922 927
4. K.D. Lillemoe, S. Kaushal, J.L. Cameron, T.A. Sohn, H.A. Pitt, and C.J. Yeo Distal pancreatectomy: indications and outcomes in 235 patients Ann Surg 229 1999 693 698 discussion 698-700
5. T.A. Sohn, C.J. Yeo, J.L. Cameron, L. Koniaris, S. Kaushal, and R.A. Abrams Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators J Gastrointest Surg 4 2000 567 579
6. C.D. Johnson, G. Schwall, J. Flechtenmacher, and M. Trede Resection for adenocarcinoma of the body and tail of the pancreas Br J Surg 80 1993 1177 1179
7. M. Shoup, K.C. Conlon, D. Klimstra, and M.F. Brennan Is extended resection for adenocarcinoma of the body or tail of the pancreas justified? J Gastrointest Surg 7 2003 946 952 discussion 52
8. S. Partelli, S. Crippa, G. Barugola, D. Tamburrino, P. Capelli, and M. D'Onofrio Splenic artery invasion in pancreatic adenocarcinoma of the body and tail: a novel prognostic parameter for patient selection Ann Surg Oncol 18 2011 3608 3614
9. M. Kanda, T. Fujii, T.T. Sahin, A. Kanzaki, S. Nagai, and S. Yamada Invasion of the splenic artery is a crucial prognostic factor in carcinoma of the body and tail of the pancreas Ann Surg 251 2010 483 487
10. K. Shimada, Y. Sakamoto, T. Sano, and T. Kosuge Prognostic factors after distal pancreatectomy with extended lymphadenectomy for invasive pancreatic adenocarcinoma of the body and tail Surgery 139 2006 288 295
11. C. Sperti, M. Berselli, and S. Pedrazzoli Distal pancreatectomy for body-tail pancreatic cancer: is there a role for celiac axis resection? Pancreatology 10 2010 491 498
12. H. Oettle, S. Post, P. Neuhaus, K. Gellert, J. Langrehr, and K. Ridwelski Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial JAMA 297 2007 267 277
13. D.B. Evans, G.R. Varadhachary, C.H. Crane, C.C. Sun, J.E. Lee, and P.W. Pisters Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head J Clin Oncol 26 2008 3496 3502
14. H. Ohigashi, O. Ishikawa, H. Eguchi, H. Takahashi, K. Gotoh, and T. Yamada Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer Ann Surg 250 2009 88 95
15. H. Takahashi, H. Ohigashi, K. Gotoh, S. Marubashi, T. Yamada, and M. Murata Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer Ann Surg 258 2013 1040 1050
16. M.M. Assifi, X. Lu, G. Eibl, H.A. Reber, G. Li, and O.J. Hines Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials Surgery 150 2011 466 473
17. M.S. Talamonti, W. Small Jr., M.F. Mulcahy, J.D. Wayne, V. Attaluri, and L.M. Colletti A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma Ann Surg Oncol 13 2006 150 158
18. R.R. White, H.B. Xie, M.R. Gottfried, B.G. Czito, H.I. Hurwitz, and M.A. Morse Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer Ann Surg Oncol 12 2005 214 221
19. L. Sobin, M. Gospodarowicz, and C. Wittekind TNM classification of malignant tumors 7th ed 2009 Wiley-Liss New York
20. S. Hirano, S. Kondo, T. Hara, Y. Ambo, E. Tanaka, and T. Shichinohe Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic body cancer: long-term results Ann Surg 246 2007 46 51
21. National Comprehensive Cancer Network. NCCN Guidelines. Available from: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp.
22. H. Takahashi, H. Ogawa, H. Ohigashi, K. Gotoh, T. Yamada, and M. Ohue Preoperative chemoradiation reduces the risk of pancreatic fistula after distal pancreatectomy for pancreatic adenocarcinoma Surgery 150 2011 547 556
23. C.E. Kitami, I. Kurosaki, Y. Kawachi, K. Nihei, Y. Tsuchiya, and T. Nomura Portal vein infusion chemotherapy with gemcitabine after surgery for pancreatic cancer Surg Today 43 2013 33 39
24. H. Takahashi, H. Ohigashi, O. Ishikawa, K. Gotoh, T. Yamada, and S. Nagata Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine-based chemoradiation therapy for resectable pancreatic cancer Ann Surg 255 2012 95 102
25. D.S. Lu, H.A. Reber, R.M. Krasny, B.M. Kadell, and J. Sayre Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT AJR Am J Roentgenol 168 1997 1439 1443
26. D.B. Evans, T.A. Rich, D.R. Byrd, K.R. Cleary, J.H. Connelly, and B. Levin Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas Arch Surg 127 1992 1335 1339
27. NCI Common Terminology Criteria for Adverse Events (CTCAE) v.4. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/About.html.
28. C. Bassi, C. Dervenis, G. Butturini, A. Fingerhut, C. Yeo, and J. Izbicki Postoperative pancreatic fistula: an international study group (ISGPF) definition Surgery 138 2005 8 13
29. M.N. Wente, C. Bassi, C. Dervenis, A. Fingerhut, D.J. Gouma, and J.R. Izbicki Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS) Surgery 142 2007 761 768
30. H. Takahashi, H. Ohigashi, O. Ishikawa, H. Eguchi, K. Gotoh, and T. Yamada Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival Ann Surg 251 2010 461 469
31. M.B. Slidell, D.C. Chang, J.L. Cameron, C. Wolfgang, J.M. Herman, and R.D. Schulick Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis Ann Surg Oncol 15 2008 165 174
32. J.M. Winter, J.L. Cameron, K.A. Campbell, M.A. Arnold, D.C. Chang, and J. Coleman 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience J Gastrointest Surg 10 2006 1199 1210 discussion 1210-1
33. M. Kayahara, H. Nakagawara, H. Kitagawa, and T. Ohta The nature of neural invasion by pancreatic cancer Pancreas 35 2007 218 223
34. T. Conroy, F. Desseigne, M. Ychou, O. Bouche, R. Guimbaud, and Y. Becouarn FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 2011 1817 1825
35. D.D. Von Hoff, T. Ervin, F.P. Arena, E.G. Chiorean, J. Infante, and M. Moore Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine N Engl J Med 369 2013 1691 1703